Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 103 P129 | DOI: 10.1530/endoabs.103.P129

BSPED2024 Poster Presentations Obesity 2 (7 abstracts)

First year outcomes in a paediatric complications of excess weight (CEW) service

Khadiga Osman 1 , Neil Wright 2 & Elspeth Ferguson 2


1University of Sheffield School of Medicine, Sheffield, United Kingdom; 2Sheffield Children’s NHS Foundation Trust, Sheffield, United Kingdom


Background: We aimed to evaluate first year outcomes for our Complications of Excess Weight (CEW) Service based at our tertiary paediatric centre. Children and young people with significant obesity in our region and referred to the service, receive tier 3 weight management support, including intensive lifestyle and psychosocial assistance both through clinics and in the community, including support delivered at home. Referral criteria are an age less than 16 years ay referral with a Body Mass Index Standard Deviation Score (BMI SDS) >3.3 or BMI >98th centile with 2 obesity associated complications.

Methodology: Using routinely collated data, demographic details were recorded and mean and median BMI SDS were measured at baseline (programme entry), and after 6 months and 12 months intervention for all participants. Changes in BMI SDS were compared. A fall of 0.25 BMI SDS was considered clinically significant.

Results: A total of 277 patients had accessed CEW services up until the end of August 2023. The majority were of white ethnicity (44%), from the most deprived decile (43%) and were secondary school aged (45%). Twelve-month follow-up data was available for 54 patients (19.5%). Mean and median BMI SDS outcomes were compared between baseline and 12 months. Mean BMI SDS fell by 0.20 over 12 months across the whole cohort. Females achieved a greater BMI SDS reduction than males, with a 0.21 mean decrease in BMI SDS, compared to males (0.18 mean BMI SDS decrease). When broken down by age, both pre-school aged children and primary school aged children demonstrated clinically significant BMI SDS reductions (reduction of 1.26 and 0.40 BMI SDS respectively). Secondary school aged children did not demonstrate clinically significant results. Those who were prescribed medications Liraglutide or Semaglutide (n = 7), showed greater BMI SDS reduction than those not prescribed medication (mean BMI SDS loss of 0.21 with medication compared to the mean BMI SDS gain of 0.01 without medication).

Conclusion: These preliminary results for children aged 11 years and younger are encouraging, but there is still a need to consider strategies to improve outcomes, particularly in adolescents and to determine if positive results are sustained.

Volume 103

51st Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes

Glasgow, UK
08 Oct 2024 - 10 Oct 2024

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.